A Novel Para-Amino Salicylic Acid Magnesium Layered Hydroxide Nanocomposite Anti-Tuberculosis Drug Delivery System with Enhanced in vitro Therapeutic and Anti-Inflammatory Properties

Bullo Saifullah1,2, Palanisamy Arulselvan3,4, Mohamed E El Zowalaty5, Woan Sean Tan3, Sharida Fakurazi6, Thomas J Webster7, Rabia Baby6, Mohd Zobir Hussein1

1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 2Department of Management Sciences and Technology, The Begum Nusrat Bhutto Women University Sukkur, Sukkur, Sindh, 65170, Pakistan; 3Laboratory for Vaccine and Immunotherapeutics, Institute of Biosciences, University Putra Malaysia, Serdang, Selangor, 43400, Malaysia; 4Muthayammal Centre for Advanced Research, Muthayammal College of Arts and Science, Namakkal, Tamil Nadu, 637408, India; 5Zoonosis Science Center, Department of Microbiology and Immunology, Uppsala University, Uppsala, Sweden; 6Department of Human Anatomy, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia; 7Department of Chemical Engineering, Northeastern University, Boston, MA, USA.

Correspondence: Mohd Zobir Hussein
Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology, ITMA, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Tel: +60 397698092
Email: mzobir@upm.edu.my

Introduction: Mycobacterium tuberculosis infections are associated with severe local inflammatory reactions, which may be life-threatening and lead to tuberculosis pathogenesis and associated complications. Inorganic nanolayers have been vastly exploited for biomedical applications (especially in drug delivery) because of their biocompatible and biodegradable nature with the ability to release a drug in a sustained manner. Herein, we report a new nanodelivery system of inorganic nanolayers based on magnesium layered hydroxides (MgLH) and a successfully intercalated anti-tuberculosis drug para-aminosalicylic acid (PAS).

Methods: The designed anti-tuberculosis nanodelivery composite, MgLH-PAS, was prepared by a novel co-precipitation method using MgNO3 as well MgO as starting materials.

Results: The designed nano-formulation, PAS-MgLH, showed good antimycobacterial and antimicrobial activities with significant synergistic anti-inflammatory effects on the suppression of lipopolysaccharide (LPS) stimulated inflammatory mediators in RAW 264.7 macrophages. The designed nano-formulation was also found to be biocompatible with human normal lung cells (MRC-5) and 3T3 fibroblast cells. Furthermore, the in vitro release of PAS from PAS-MgLH was found to be sustained in human body simulated phosphate buffer saline (PBS) solutions of pH 7.4 and pH 4.8.

Discussion: The results of the present study are highly encouraging for further in vivo studies. This new nanodelivery system, MgLH, can be exploited in the delivery of other drugs and in numerous other biomedical applications as well.

Keywords: Mycobacterium tuberculosis, magnesium layered hydroxides, biomaterial, sustained release, anti-tuberculosis, anti-inflammatory

Introduction: Tuberculosis is a devastating bacterial infectious disease caused by Mycobacterium tuberculosis (MTB) or tubercle bacilli.1 It existed for centuries and despite technological advancements, we have still not been able to eradicate it. There are only two new drugs that have been found for tuberculosis treatment in the last five decades.2 With the currently best available anti-TB drugs, the treatment lasts from 6 to 24 months, depending on the type of TB disease.3 According to the latest global tuberculosis...
In 2020, there were about 10 million new incidents of TB cases worldwide in the year 2019. There were an estimated 1.2 million (range, 1.1–1.3 million) TB deaths among HIV-negative people in 2019.1 Tuberculosis is associated with a severe local inflammatory reaction which may be life-threatening and leads to pathogenesis and associated complications. This results in the activation of the innate immune response components and the main recruiters of immune cells, such as polymorphonuclear and mononuclear phagocytes. It also results in the stimulation of numerous primary pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin 6, and interleukin 1β by the mycobacterium.4–7 These inflammatory reactions cause severe damage to the site of the infection.5–7

In the present study, we investigated the anti-inflammatory potential of these nanocomposites on LPS-stimulated RAW 264.7 macrophages. PAS is an effective drug, but because of its side effects such as epigastric distress, nausea, anorexia, vomiting, and abdominal cramps or diarrhea, it is no longer used for drug-susceptible TB but is still being used for the treatment of multi-drug resistant TB (MDR-TB). Biocompatible and biodegradable formulations with anti-TB, anti-inflammatory and sustained release properties would be very useful to overcome these problems.8,9

A layered double hydroxide (LDH) has a basic structure derived from brucite by replacing some of the divalent cations with trivalent ones (such as Al3+, Fe3+ and Cr3+, etc.), to create a positive charge in the layers.10–13 This positive charge is balanced by counter anions between the layers such as nitrate, carbonates, water molecules and most importantly, pharmaceutical drugs in the neutral form with lone pairs or being negatively charged.14 Non-toxic characteristics of the anion make them ideal candidates for biomedical and drug delivery applications.10,15–17 In this study, we have developed magnesium-layered hydroxides as a drug delivery system without the addition of any trivalent ions in the inorganic layers. Magnesium was chosen based on its high biocompatibility and nutritional value. We intake green vegetables daily where Mg2+ is the central ion present in chlorophyll in vegetables and plants. It is a vital divalent mineral for humans, which is responsible for many enzymatic reactions, such as energy metabolism, and is a vital component of soft tissue forming cells as well as bones and is the most abundant divalent cation in human cells.18–21

Different types of layered double hydroxides (LDHs) (eg, Mg/Al-LDHs, Zn/Al-LDHs and in some studies Fe3+ replacing Al3+) including zinc layered hydroxides (ZLH) have been exploited as drug delivery agents. They have been reported to be suitable drug delivery agents because of their tendency to release drugs in a sustained manner and be highly biocompatible as well as biodegradable.16,22–25 PAS has been loaded with zinc layered hydroxides (ZLH) and Zn/Al-LDHs.26,27 Compared to these, MgLH is more suitable as it does not require trivalent ions like LDHs and more importantly, magnesium is more biocompatible than Zn2+, as we consume more magnesium in green vegetables on a regular basis.28

Magnesium layered hydroxide (MgLH) is a non-toxic material that has a wide range of applications such as in cosmetic products, serving as a catalyst in flame-retardants and has been used as inorganic absorbents, etc.29–31 MgLH has a layered structure in which the hydroxide ions surround the magnesium ion in an octahedral manner.30 Infinite layers are formed by these octahedral units by edge-sharing with hydroxide ions in the planes of the layers. In a three-dimensional view, layers stack on top of one another.30,32,33 Biocompatible and biodegradable formulations with anti-TB and anti-inflammatory as well as sustained release properties would be very useful to overcome these problems.34,35

Many attempts have been made to form a sustained release formulation that could help reduce such side effects such as using buffered tablets, granules, coated tablets and the salt of acids.36–38 A biocompatible and biodegradable nanocomposite formulation with sustained-release properties would also be helpful in minimizing side effects as the entire drug is not exposed to the human body simultaneously. Instead, the drug is released in a sustained manner which would decrease side effects and would maintain the bioavailability of drugs over a longer time period.

For all of the above reasons, in this study, we successfully intercalated para-aminosalicylic acid (PAS) into magnesium layered hydroxides (PAS-MgLH) by two different methods. In the first method, we used magnesium oxide as the starting material while in the second method, hydrated magnesium nitrate was used instead.

**Materials and Methods**

**Chemicals**

Analytical-grade chemicals were used without any further purification. MgNO3·6H2O and MgO were obtained from Sigma-Aldrich (Saint Louis, MO, USA) and methanol was bought from Ajax Finechem (Sydney, Australia). In all experimental work, deionized water was used.
Cell Culture
Fibroblast 3T3-Swiss albino (ATCC® CCL-92™) cells, mouse macrophages (RAW 264.7 cells) and human lung fibroblast MRC-5 (ATCC® CCL-171™) cells were supplied by ATCC (Manassas, VA, USA). Dulbecco’s modified Eagle medium and RPMI 1640 media containing 10% fetal bovine serum were utilized in the cell culture work. Penicillin at 100 units/mL and streptomycin at 50 µg/mL were added to the growth media. A humidified atmosphere with 5% CO₂, at a temperature of 37 °C, was maintained for all cell culture work.

Preparation of Nanocomposite-A Using MgO as the Starting Material
Magnesium oxide (MgO), 0.2 g, was added into 50 mL of deionized water and stirred for 15 minutes. To this dispersion solution, 50 mL (25 mL DMSO + 25 mL H₂O) of a 0.4 M solution of PAS was added. The pH of the solution was raised to basic by the slow addition of a 0.5 M solution of sodium hydroxide and the sample was subjected to an oil bath thermal agitation at 70 °C for one day. On the next day, the sample was washed several times thoroughly with water and then with acetone. Then, the sample was dried in an oven for 2 days at 70 °C and ground to a powder. The sample prepared by this method was labeled as Nanocomposite-A.

Preparation of Nanocomposite-B Using Magnesium Nitrate Hexahydrate as the Starting Material
Magnesium nitrate hexahydrate (1 g) was dissolved in 50 mL of deionized water and stirred for 15 minutes. With this solution, 50 mL (25 mL DMSO + 25 mL H₂O) of a 0.4 M solution of PAS was added. The pH of the solution was raised to basic by the slow addition of 0.5 M sodium hydroxide and the sample was subjected to oil bath thermal agitation at 70 °C for one day. On the next day, the sample was washed many times thoroughly with water and then acetone. After that, the sample was dried in an oven for 2 days at 70 °C and ground to a powder for further characterization. The sample prepared by this method was labeled as nanocomposite-B.

Characterization
X-Ray Diffraction
For the X-ray diffraction studies, a Shimadzu XRD-6000 diffractometer (Tokyo, Japan), was used. CuKα radiation at 30 kV and 30 Ma was set to record the PXRD patterns. The PXRD patterns were recorded in the 20 range of 2–60° with a scanning speed of 0.5 degrees per minute. The samples were ground to a powder before recording the PXRD patterns.

FTIR Analysis
A Perkin-Elmer 100 series-spectrophotometer was used to record the Fourier transform infrared (FTIR) spectra of the materials, over a range of 400–4000 cm⁻¹. Each sample was analyzed by a direct method where the sample was directly put on the FTIR sample analyzer to record the spectrum.

Thermogravimetric Analysis
A Mettler Toledo instrument (Greifensee, Switzerland), was used for the thermogravimetric and differential thermogravimetric (TGA-DTG) analyses. For the thermal analysis, samples were subjected to heating from 25°C to 1000°C with an increase at a rate of 10°C/minute under a continuous nitrogen purge. Mass loss was observed with an increase in temperature.

Transmission Electron Microscopy (TEM) Analysis
The surface morphology of the sample was analyzed by a Transmission Electron Microscope (TEM). The sample was dispersed in deionized water and sonicated for 5 minutes and a few drops of the samples were poured on the TEM sample grid. After that, the samples were dried at room temperature overnight before analysis.

Dynamic Light Scattering (DLS) Analysis
The DLS technique was applied for the determination of particle size distribution in a solution as termed hydrodynamic size. The samples were put in deionized water and sonicated for 5 minutes before DLS analysis.

UV/Vis Spectroscopic Analysis
For optical properties and controlled-release studies, a Shimadzu UV-1650-PC UV/Vis spectrophotometer was employed. Initially, the pure drug, PAS lambda max, the wavelength of maximum absorption was determined to be 265nm. This wavelength was selected for the drug release studies.

HPLC Analysis
The drug loading was quantified by a Sykam HPLC system with an auto-injector Sykam 5300, a Sykam S3250 UV/Vis detector and the Sykam quaternary pump system 5300 made in Germany, with a Zorbax Rx-Sil column of 4.6×150 mm,
and with a 5 μm particle size (Agilent). The standard solutions of PAS ie, 10ppm, 20ppm, 30 ppm, 40ppm and 50ppm were prepared from the stock solution of PAS. The empty MgLH (without drug) sample solution was also prepared by dissolving it in a HCl solution for any matrix effect in the HPLC analysis. The mobile phase consisted of a 17.5 mM potassium phosphate buffer as solvent-A with a pH of 3.5 adjusted by phosphoric acid and methanol as solvent B. Before HPLC analysis, the column was saturated with the mobile phase for 30 minutes.

Sustained-Release Study
Human body-simulated, 0.1 M phosphate buffer saline (PBS) solutions of pH values of 7.4 (blood pH) and 4.8 (intracellular lysosomal pH) were used to study the sustained release of PAS from the inorganic galleries of the nanocomposite. Approximately 0.4 mg each of the Nanocomposite-A and B were placed in 3.5 mL of pH 7.4 and 4.8 PBS solutions, and the absorbance at the wavelength $\lambda_{\text{max}} = 265 \text{ nm}$ was selected for the UV/Vis spectrophotometer to study drug release from the nanocomposites. The nanocomposites were placed under constant shaking at 37 °C and at different times, aliquots were taken and replaced back after taking a reading using a UV/Vis spectrophotometer.

Antimicrobial Susceptibility Test
The drug susceptibility testing of the nanocomposites was carried out using the BBL nonradiometric fluorescence-based method of MGIT 960 against *Mycobacterium tuberculosis* (ATCC® 25618™) and the MICs of the nanocomposites were determined as previously described. The Mycobacteria Growth Indicator Tube (MGIT) with BACTEC MGIT 960 growth supplement for drug susceptibility testing was used in an MGIT 960 instrument (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) as described previously. The Mycobacteria Growth Indicator Tube (MGIT) with BACTEC MGIT 960 growth supplement for drug susceptibility testing was used in an MGIT 960 instrument (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) as described previously.

Microbial Growth-Inhibition Kinetics
The antimicrobial effect of the as-synthesized Nanocomposites-A and B on the growth kinetics of *Staphylococcus aureus* (ATCC®43300™), *Pseudomonas aeruginosa* (ATCC®27853™), *Escherichia coli* (ATCC®25922™), and *Candida albicans* (ATCC®24048™) (ATCC, Manassas, VA, USA) was determined as previously described. The percentage inhibition of each nanocomposite against each microorganism was calculated according to the following equation as previously described:

$$\text{Inhibition rate} = 1 - \left[ \frac{\text{CFU}_{\text{treated}}}{\text{OD}_{\text{control}}} \right] \times 100 \text{ (1)}$$

The efficiency of the nanocomposites to inhibit the growth of the microorganisms was determined by the differences in the equivalent number of colony-forming units before and after treatment as the percentage of microbes that were inhibited by the nanocomposites; this was calculated from the previous equation.

Cell Viability Assays
The cytotoxicity of the nanocomposites on 3T3 fibroblasts, RAW 264.7 cells and normal lung fibroblast cells (MRC-5) was evaluated by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) MTT assays. In this experiment, cells were seeded in the 96 well plates (at a cell density of $1\times10^4/\text{well}$) at various concentrations and incubated overnight to attach the cells. After 24 hrs, the seeded cells were exposed to different concentrations of nanoparticles and incubated for another 24 hours at 5% CO$_2$ and 37 °C. About 20 μL of the MTT working solution (5mg/mL in phosphate-buffered solution) was added to the entire well and incubated at 37 °C for 3 hrs. Finally, the culture media were removed after centrifugation and formazan crystals were dissolved in 100 μL of DMSO. The absorbance values were measured at 570 nm using a microplate reader and cell viability percentage was calculated according to the previously described method.

Determination of Nitric Oxide and Pro-Inflammatory Cytokine Production
The macrophage RAW 264.7 cells were seeded in 6 well plates and incubated overnight. After the incubation period, the seeded cells were pre-treated with different concentrations of nanoparticles and a positive control drug, dexamethasone, for 2 hrs. Further, inflammation was induced by LPS stimulation (1 μg/mL) in pre-treated cells for an additional 24 hrs and the cell culture supernatant was harvested and stored at −20 °C until further use. The nitric oxide concentration in the cell culture media was quantified according to previous methods. Briefly, the effect of nanoparticles on RAW264.7 cell production was determined based on the Griess reaction and the remaining media was used to quantify the production of pro-inflammatory cytokines (IL-6, IL-1β and TNF-α) with ELISA kits (R&D Systems, Minneapolis, USA) according to the manufacturer’s guidelines.
Statistical Analysis
The biological assays were conducted from three different independent investigations and expressed as the mean ± standard deviation (SD). Data are presented as the mean ± SD and P < 0.05 and P < 0.001 were considered as statistically significant. Significant differences were examined using analysis of variance (ANOVA) with SPSS 20.0 software (SPSS Inc., Chicago, IL, USA).

Results
X-Ray Diffraction and Spatial Orientation of PAS
Figure 1 shows the X-ray diffraction patterns for the magnesium layered hydroxides (MgLH), the free drug, para-aminosalicylic acid (PAS), Nanocomposite-A and Nanocomposite-B. The magnesium layered hydroxides (MgLH) showed four characteristic reflection peaks: 001, 100, 101 and 102 at a 2ϴ value of about 19°, 33°, 38° and 52°, respectively. The XRD patterns of Nanocomposite–A and Nanocomposite–B show that the position of the peaks shifted to a lower 2ϴ value of 7.0°. In Nanocomposite-A and Nanocomposite–B, the basal spacings (d-spacings) increased from 4.73 Å to 12.08 Å, and 11.06 Å, respectively. The increased basal spacings in both nanocomposites strongly suggest the successful intercalation of PAS into the interlayer galleries of MgLH.

Furthermore, the complete disappearance of reflection peaks, namely 001, 100, 101, 102 and the appearance of the reflection peaks at a lower 2ϴ value, with higher basal spacing (d-spacing) value, indicates the pure phase of both the nanocomposites of PAS-MgLH. The XRD patterns of the Nanocomposite–A show three reflections, with the first, second and third with a basal spacing of 12.08 Å, 6.29 Å and 4.24 Å, respectively. On the other hand, Nanocomposite-B (Figure 1A) also shows the three reflections with a basal spacing of 11.65 Å, 6.36 Å and 4.35 Å. These reflections suggest that both nanocomposites are highly crystalline. Thus, the XRD results confirmed the successful intercalation of PAS into the interlayer galleries of MgLH and that the resulting composites are highly crystalline and relatively pure.

The spatial orientation of PAS in the interlayer galleries of MgLH was proposed by calculating the average basal spacing of all the PXRD reflections in both Nanocomposite–A and Nanocomposite–B. The average basal spacing of the Nanocomposite–A was found to be approximately 12.47 Å and the Nanocomposite–B was 12.49 Å. The three-dimensional molecular size of PAS in the X, Y and Z axes have been reported to be 9.4 Å, 7.1 Å, and 4.2 Å.
and 2.9 Å, respectively.\textsuperscript{50} By subtracting the inorganic layer thickness of 4.8 Å from the average basal spacing value of 12.47 Å and 12.49 Å, the obtained value is 7.67 Å and 7.69 Å for Nanocomposite-A and Nanocomposite-B, respectively. These remaining values of 7.67 Å and 7.69 Å are near to the horizontal molecular orientation (Y-axis) which is 7.1 Å for PAS. This suggests that PAS was oriented in the horizontal form between the interlayer galleries of MgLH with a slightly tilted orientation in both nanocomposites. This tilted form is more favorable for the electrostatic interaction and the formation of hydrogen bonds between PAS and the host, MgLH. Figure 1B shows the orientation of PAS in Nanocomposite-A, and a similar orientation of PAS in Nanocomposite-B is expected.

**Infrared Spectroscopy**

Infrared spectroscopy was used as supporting evidence for the successful intercalation of anions into metal hydroxide nanolayers. In addition to XRD analysis, the intercalation of PAS was further supported by Fourier Transformed Infrared (FTIR) spectroscopy. Figure 2 shows the FTIR spectra of the free drug (PAS), magnesium layered hydroxides (MgLH), Nanocomposite-A and Nanocomposite-B. The FTIR spectrum of free PAS shows characteristics of the PAS functional group absorption bands, such as O–H, =C–H, and N–H at high wavenumbers, characteristic carboxyl (C=O) bands for the carboxylic acid group at 1609 cm\(^{-1}\), aromatic ring C-C bond at 1529 and 1433 cm\(^{-1}\) and the characteristic alcohol peaks, C-O and O-H at 1273 cm\(^{-1}\) and 1190 cm\(^{-1}\), respectively.\textsuperscript{51–53} Non-intercalated MgLH shows only a few absorption bands due to the hydroxyl group at 3694 cm\(^{-1}\) and the lattice vibration for the Mg-O absorption band at 1419 cm\(^{-1}\) and 1010 cm\(^{-1}\).\textsuperscript{54,55} The FTIR spectra of both of the nanocomposites (A and B) show the absorption bands of the PAS together with bands for MgLH, which strongly support the XRD result for the successful intercalation of PAS into MgLH. Detailed absorption bands of free PAS and both of the nanocomposites (A and B) are given in Table 1.\textsuperscript{48,51,54,56}

**HPLC, ICP and TGA Analyses**

The presence of magnesium, which is the major component of MgLH, was determined using ICP analysis and was found to be about 45% in both nanocomposites (A and B). Drug (PAS) loading was determined by high-performance liquid chromatography (HPLC) using a previously developed protocol.\textsuperscript{57} The loading of PAS was found to be about 23% and 22% in Nanocomposite-A and Nanocomposite-B, respectively. In the thermal analysis, 15% and 11% weight loss occurred at about 50 °C for the Nanocomposite-A and Nanocomposite-B, respectively, which can be attributed to the physically adsorbed water molecules on the surface of the nanocomposites. The empirical formula was determined using drug loading, ICP-OES and TGA analysis for both the nanocomposites and is as given below.

Nanocomposite A: \([\text{Mg}_{1.88} (\text{OH})_2](\text{C}_7\text{H}_6\text{NO}_3)\text{O}_{0.15}\text{H}_2\text{O}\)

Nanocomposite B: \([\text{Mg}_{1.87} (\text{OH})_2](\text{C}_7\text{H}_6\text{NO}_3)\text{O}_{0.14}\text{H}_2\text{O}\)

**Transmission Electron Microscopy and Particle Size Distribution Studies**

The transmission electron micrographs (TEM) revealed that the nanocomposite particles were well dispersed with a
uniform circular shape as shown in Figure 3A and B, for the Nanocomposite-A and Nanocomposite-B, respectively. The particle size and size distribution were determined from the TEM micrographs using UTHSCSA Image Tool software. About 105 different particles (N) were randomly selected for each nanocomposite and their diameters were measured using

| Assignment | PAS | Nanocomposite-A | Nanocomposite-B |
|------------|-----|-----------------|-----------------|
| $\nu$ as (N-H) | 3490 | Overlapped with O-H stretching at 3352 | Overlapped with O-H stretching at 3344 |
| $\nu$ s (N-H) | 3381 | | |
| $\nu$(O-H) in the layer/H$_2$O | 3694 | 3352 | 3344 |
| $\nu$ (C=O) in COOH | 1609 | 1609 | 1609 |
| $\nu$ O-H ring stretching | 3020, 1283, 1163 | 1286 | 1285 |
| $\nu$ (C-C) assym and sym: stretching of aromatic ring | 1519, 1433 | 1452 | 1449 |
| $\nu$ aromatic (C-C-C) ring sym bending | 525 | 529 | 521 |

Table 1 FTIR Assignments (in nm) of PAS and Its Nanocomposites (A and B)

Figure 3 Transmission electron micrographs of Nanocomposite-A (A), Nanocomposites-B (B) and particle size distribution of Nanocomposite-A (C) and Nanocomposite-B (D).
the software. The average diameter in Nanocomposite-A was found to be 120 nm with a particle size distribution of 70–150 nm. For the Nanocomposite-B, the average diameter was determined to be 195 nm with an overall particle size distribution of 100–300 nm. Figure 3C and D show the particle diameter and particle size distribution of Nanocomposite-A and Nanocomposite-B, respectively.

Dynamic Light Scattering (DLS) Analysis
The particle size of both of the nanocomposites was determined using DLS analysis using a zeta sizer. The particle size distribution of Nanocomposite-A was found to be in the range of 50 nm to 600 nm. According to the cumulative distribution frequency, 80% of the particles were found to be equal to or less than 142 nm as shown in Figure 4A. The particle distribution for the Nanocomposite-B was found to be 150 nm to 600 nm. According to the cumulative distribution frequency for the Nanocomposite-B, 80% of the particles were found to be equal to or less than 220 nm as shown in Figure 4B. The overall particle size distribution was found to be larger than the TEM particle size distribution which can be ascribed to the hydrodynamic size and agglomeration/accumulation of the particles in an aqueous solution.58

In vitro Release Study
The in vitro release of PAS from the Nanocomposite-A and Nanocomposite-B were carried out in human body simulated phosphate buffer saline (PBS) solutions of pH 7.4 and 4.8. Figures 5A and B show the in vitro release profiles of PAS from the Nanocomposite-A in a PBS solution of pH 7.4 and pH 4.8, respectively. Under both in vitro conditions, PAS took about 1400 minutes for about a 100% release. PAS took almost the same time (i.e., 1400 minutes) to be 100% released, as it took for Nanocomposite-A. The release behavior of PAS from both nanocomposites was found to be sustained without any sign of burst release, which is most commonly found in the release of the drugs from their layered double hydroxide galleries.27,50 The release duration of 1400 minutes, or almost 24 hours, indicated that the PAS concentration could be possibly maintained in the human body for 24 hours by the designed nanodelivery formulation. This will significantly improve the bioavailability of PAS, which will certainly improve the therapeutic efficacy.

Antimicrobial Susceptibility Tests
The synthesized nanocomposites showed antimycobacterial activity as shown in Figure 6. The MICs of the Nanocomposites (A and B) were found to be 15.4 µg/mL and 20.1 µg/mL, respectively compared to the free drug, PAS, which was 5.5 µg/mL. The percent loading of PAS in Nanocomposite-A and Nanocomposite-B was found to be 23% and 22%, respectively. Based on the percent loading of PAS, the amount of PAS in the Nanocomposite-A and Nanocomposite-B was found to be 3.45 µg/mL and 4.42 µg/mL, respectively, which is termed as the effective MIC. Therefore, the effective MICs for the nanocomposites were relatively smaller compared to the free drug, PAS, which was 5.5 µg/mL, suggesting an improved therapeutic efficacy of the nanocomposites.

![Figure 4](https://doi.org/10.2147/IJN.S297040) (A and B) show the hydrodynamic size for Nanocomposite-A and Nanocomposite-B, respectively.
Antimicrobial Results

The results of the antimicrobial testing using growth kinetics showed that the PAS nanocomposites (A and B) have antibacterial activity against Gram-positive bacteria (*S. aureus*), Gram-negative bacteria (*E. coli*), and antifungal activity against *Candida albicans*, as shown in Figure 7A and B. This additional antibacterial activity of the PAS nanocomposites as compared to the free PAS, which lacks antimicrobial activity, is advantageous in the treatment of polymicrobial infections that might be associated with tuberculosis infections.

Cytotoxicity Studies

To evaluate the cytotoxicity profile, the free drug PAS, empty carrier (MgLH) and designed anti-TB nanocomposites (A and B) were treated with 3T3 and MRC-5 cells. The different concentrations, ie, 1.56 μg/mL to 100 μg/mL, of the samples were incubated for 72 hours with these cell lines. As shown in Figure 8A and B, more than 80% viability of both cell lines was measured at the highest concentration of 100 μg/mL and after 72 hours of incubation. These results suggest good cytocompatibility of the designed anti-TB nanocomposites.

Effect of the Nanocomposites on RAW 264.7 Macrophage Viability

Cell viability was investigated by MTT assays after treatment with the nanocomposites, free drug PAS, and pristine empty MgLH. As shown in Figure 9, at the higher concentration of the nanocomposites, pure drugs and carriers showed a cytotoxic effect on macrophages. However, at lower concentrations of nanoparticles, carrier and pure drugs did not show any significant cell cytotoxicity, at least up to 25 μg/mL. Therefore, we have selected nontoxic concentrations (at 10 μg/mL) of the nanocomposites, drugs and carriers for further in vitro biological experiments.
Effect of the Nanocomposites on Lipopolysaccharide Stimulated Production of Pro-Inflammatory Molecules in RAW 264.7 Cells

The inflammatory process involves various immune cells, mainly monocytes, macrophages and dendritic cell activation. Among all of the cells, macrophages are more sensitive and known to play a crucial role in normal defensive reactions and to release the numerous inflammatory mediators by the induction of inflammatory cytokines and microbial substances, such as lipopolysaccharides (LPSs). Most biomedical researchers have investigated the anti-inflammatory potential of compounds using LPS induced in vitro and in vivo experimental models particularly with macrophages and monocytes.59

LPS-stimulated macrophages induce numerous cellular events, such as the production of key inflammatory mediators which include NO, IL-6, IL-1β and TNF-α, and the production of these inflammatory molecules in the cell culture media or serum of LPS-induced macrophages or experimental animals, which are consistent markers of inflammation. Based on these inflammatory events, we hypothesized that suppression of these inflammatory mediators in LPS stimulated macrophages may serve as the foundation for potential drug development against various inflammatory-associated diseases. Hence, in this investigation, the anti-inflammatory effects of the samples were evaluated on LPS stimulated macrophages, RAW 264.7 cells. Dexamethasone, a plant-derived compound, was used as a positive control for all the experiments and doses of positive control drugs were followed according to previous findings.60,61

NO and other pro-inflammatory cytokines, including IL-6, IL-1β and TNF-α, are some of the key inflammatory mediators in numerous vital organs. In the present study, we investigated the effect of nanocomposites, drugs and carriers on the production of NO, IL-6, IL-1β and TNF-α in LPS induced RAW 264.7 cells. As depicted in Figures 10 and 11A–C, LPS alone significantly increased the level of NO production when compared to the control, without any treatment. In Figure 11, the nanocomposites, carriers and pure drugs showed a significant inhibitory effect on NO production in LPS-stimulated RAW 264.7 cells. However, in the production of pro-inflammatory cytokines, Nanocomposite B seemed to show a better significant inhibitory effect when compared to Nanocomposite A, the carrier and pure drugs in LPS stimulated macrophages. These inhibitory effects of the nanocomposites were comparable with the positive control drug, dexamethasone.

Discussion

The layered double hydroxide is a unique nanomaterial vastly used in various fields such as environmental remediation, catalysis, flame retardants, antimicrobial clay materials, cosmetics, biosensors, bioimaging, gene delivery, bioimplants and drug delivery carriers, etc.11,64–66 Layered double hydroxides are composed of divalent ions (Mg(II), Zn (II), Fe (II), Ni (II)) and trivalent ions (Al (III), Fe (III), Gd (III)) and both are combined to create a positive charge in the structure, making the material suitable for anions, drugs and species with a lone pair of electrons.12,16,67 The other variation of the materials includes divalent layered structures such as zinc layered hydroxides which is the most common example and for this type of
In this study, we report for the first time, the synthesis of magnesium layered hydroxide nanomaterials, MgLH, using the co-precipitation method from magnesium nitrate and magnesium oxide as the starting material. The anti-tuberculosis drug, para-aminosalicylic acid (PAS), was successfully intercalated into the interlayers. The resulting MgLH-PAS material was characterized in detail using XRD, FTIR, TEM, TGA, HPLC and ICP-AES, etc., and the results were described in each section above.

The size of the nanocomposites was determined from their TEM micrographs using image J software through the calculation of randomly selected nanoparticles. The particles were distributed in the range of 70–150 nm with an average size of 120 nm for the Nanocomposite-A. For the Nanocomposite-B, the particle size distribution was found to be between 100 and 300 nm with the average size of 195 nm. The hydrodynamic size was determined using DLS analysis. The hydrodynamic size was found to be in the range of 50 nm to 600 nm with the mean particle size of 142 nm for the Nanocomposite-A and according to the cumulative frequency distribution, more than 80% of nanoparticles were equal to or less than 142 nm in size. The particle size distribution for the Nanocomposite-B was found to be 150 nm to 600 nm with a mean particle size of 220 nm and the cumulative distribution frequency suggested that 80% of the nanoparticles were equal to or less than 220 nm. The greater hydrodynamic size can be attributed to the accumulation/agglomeration of nanoparticles in an aqueous solution. The release of the active, anti-TB drug, PAS, was found to be sustained for 24 hours without any burst release in the human body simulated PBS buffer solution. This designed MgLH-PAS nano-formulation was tested for its anti-TB assays against Mycobacterium tuberculosis bacteria and the effective
MIC was found to be 3.45 µg/mL and 4.42 µg/mL for Nanocomposite-A and Nanocomposite-B, respectively compared to PAS which was 5.5 µg/mL, suggesting improved efficacy of the later. The nanocomposites also have antimicrobial properties against gram-positive and gram-negative bacteria. In addition, the cytotoxicity profile of the samples was checked on normal cells namely 3T3 fibroblast cells and MRC-5 lung normal cells. The samples showed good biocompatibility with these cell lines. TB infection causes inflammation at the site of infection and the anti-inflammatory properties of the designed nanocomposites can be very helpful in the treatment of tuberculosis resulting in better therapeutic outcomes.

**Conclusion**

In this study, a novel MgLH delivery system was synthesized for the first time using the coprecipitation method with MgNO₃ and MgO as starting reagents for the delivery of an anti-TB drug, PAS. The designed nanocomposites were characterized in detail using XRD, FTIR, TEM, HPLC and ICP analyses. The average hydrodynamic sizes of the nanocomposites (A and B) were found to be 220 nm and 142 nm, respectively. The release of PAS from both the Nanocomposite-A and B was found to be sustained in the human body simulated PBS solutions of pH 7.4 and pH 4.8. The nanodelivery formulation (PAS-MgLH) was found to show good antimycobacterial and antimicrobial activities, significant anti-inflammatory effects on the suppression of LPS stimulated inflammatory mediators in RAW 264.7 macrophages, and most importantly, it was found to be biocompatible with human MRC-5 and 3T3 cells. The synergistic anti-inflammatory action of the designed nano-formulation will prevent severe local inflammatory reactions associated with *Mycobacterium tuberculosis* infections. These in vitro results are highly encouraging for further in vivo evaluation.
Acknowledgment
The authors would like to thank Dr Benjamin M. Geilich from the Department of Chemical Engineering, Department of Bioengineering, Northeastern University, Boston, MA, USA for his help in the antimicrobial testing experiments.

Funding
The study was funded in part by funds from the Universiti Putra Malaysia and the Ministry of Higher Education of Malaysia (grant UPM/800-3/1/GBP/2019/9678800) and Northeastern University, USA.

Disclosure
The authors report no conflicts of interest for this work.

References
1. World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020.
2. Falcke J, Hittal N, Martin A, Gupta R. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use. *Eur Respir J*. 2017;50(1):1700311. doi:10.1183/13993003.00311-2017

3. Press W. *Treatment of Tuberculosis Guidelines*. 4th ed. WHO/HTM/TB/2009.40. 20 Avenue Appia, 1211 Geneva 27, Switzerland: World Health Organization; 2010.

4. Liu CH, Liu H, Ge B. Innate immunity in tuberculosis: host defense vs pathogen evasion. *Cell Mol Immunol*. 2017;14(12):963–975. doi:10.1038/cmi.2017.88

5. Baguma R, Mbendi SK, Rodo MI, et al. Inflammatory determinants of differential tuberculosis risk in pre-adolescent children and young adults. *Front Immunol*. 2021;12:639665. doi:10.3389/fimmu.2021.639665

6. Hayford FEA, Dolman RC, Blauw R, et al. The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis. *Respir Res*. 2020;21(1):223. doi:10.1186/s12931-020-01488-9

7. Toossi Z. The inflammatory response in Mycobacterium tuberculosis infection. *Arch Immunol Ther Exp (Warsz)*. 2000;48(6):513–519.

8. Tomić M, Micov A, Pecikoza U, Stepanović-Petrović R. Chapter 1 - Sodium, Potassium, Calcium, and Magnesium: Magic Trace Elements. In: Hafkin J, Hittel N, Martin A, Gupta R. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use. *Eur Respir J*. 2017;50(1):1700311. doi:10.1183/13993003.00311-2017

9. Tomic M, Micov A, Peçikoza U, Stepanovic-Petrovic R. Chapter 1 - Inorganic nanolayers: structure, preparation, and biomedical applications. *Int J Nanomedicine*. 2015;10:24.

10. Liu JC, Qi B, Song YF. Engineering polyoxometalate-intercalated layered double hydroxide implants: potential drug delivery carriers with tissue biointegration promotion and blood microcirculation preservation. *ACS Omega*. 2018;3(12):18263–18274. doi:10.1021/acsomega.8b02532

11. Yan L, Gonga S, Zhu G, Zhang W, Chen X. Layered double hydroxide nanoparticles as an appealing nanoparticle in gene/plasmid and drug delivery system in C2C12 myoblast cells. *Int J Mol Sci*. 2019;20(1):3934–3941. doi:10.3390/ijms20131401

12. Rives V. *Layered Double Hydroxides: Present and Future*. Nova Science Pub Inc; 2001.

13. Liu JC, Qi B, Song YF. Engineering polyoxometalate-intercalated layered double hydroxides for catalytic applications. *Dalton Trans*. 2020;49(13):3934–3941. doi:10.1039/D0DT00039K

14. Bohn T. *Magnesium Absorption in Humans*. Germany: University Frankfurt; 2003.

15. Wester PO, Dyekner T. The importance of the magnesium ion. Magnesium deficiency symptomatology and occurrence. *Acta Med Scand Suppl.* 1998;661:2-.

16. Brady H. Magnesium: the forgotten cation. *Ir Med J*. 1982;80:4.

17. Severino P, Netti L, Mariani MV, Marone A. Prevention of cardiovascular disease: screening for magnesium deficiency. *Cardiol Res Pract*. 2019;2019:10. doi:10.1155/2019/4874921

18. Figueiredo MP, Cunha VRR, Leroux F, et al. Iron-based layered double hydroxide implants: potential drug delivery carriers with tissue biointegration promotion and blood microcirculation preservation. *ACS Omega*. 2018;3(12):18263–18274. doi:10.1021/acsomega.8b02532

19. Mansouri E, Tarhiz V, Yousefi V, Dilmaghani A. Intercalation and release of an anti-inflammatory drug into designed three-dimensionally layered double hydroxide nanostructure via calcination-reconstruction route. *Adsorption*. 2020;26(6):835–842. doi:10.1007/s10450-020-00217-4

20. Rabice N, Bagherzadeh M, Ghadiri AM, Salehi G, Fathi Y, Dinarvand R. ZnAl nano layered double hydroxides for dual functional CRISPR/Cas9 delivery and enhanced green fluorescence protein biosensor. *Sci Rep*. 2020;10(1):20672. doi:10.1038/s41598-020-77809-1

21. Severino P, Netti L, Mariani MV, Maraone A. Prevention of cardiovascular disease: screening for magnesium deficiency. *Acta Med Scand Suppl.* 1998;661:2.

22. Brady H. Magnesium: the forgotten cation. *Ir Med J*. 1982;80:4.
40. Walters SB, Hanna BA. Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampicin by mycobacterial growth indicator tube method. J Clin Microbiol. 1996;34(6):1565–1567. doi:10.1128/jcm.34.6.1565-1567.1996

41. Walters SB, Hanna BA. Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampicin by mycobacterial growth indicator tube method. J Clin Microbiol. 2018;56(4):1930–1936. doi:10.1128/JCM.02674-18

42. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

43. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

44. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

45. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

46. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

47. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

48. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

49. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

50. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

51. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

52. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

53. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

54. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

55. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

56. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

57. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

58. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

59. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

60. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

61. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

62. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

63. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

64. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

65. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

66. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

67. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

68. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

69. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

70. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

71. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

72. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

73. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

74. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbial growth response to inorganic nanoparticles. J Nanobiotechnol. 2013;11(1):1–20. doi:10.1186/1476-5516-11-1

75. Williams DN, Ehrman SH, Holoman TRP. Evaluation of the microbia...
